Cited by 880Sarcoma Diagnosis and TreatmentChromatin Remodeling and CancerAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 251 of the 251 references it cites were found in a registry or an index.

Ewing sarcoma

Grünewald, Thomas G. P., Cidre-Aranaz, Florencia, Surdez, Didier, Tomazou, Eleni M., de Álava, Enrique, Kovar, Heinrich, Sorensen, Poul H., Delattre, Olivier, Dirksen, Uta·2018·Nature Reviews Disease Primers

DOI 10.1038/s41572-018-0003-x

Open this paper in CoChat — free account

Abstract

Ewing sarcoma is the second most frequent bone tumour of childhood and adolescence that can also arise in soft tissue. Ewing sarcoma is a highly aggressive cancer, with a survival of 70-80% for patients with standard-risk and localized disease and ~30% for those with metastatic disease. Treatment comprises local surgery, radiotherapy and polychemotherapy, which are associated with acute and chronic adverse effects that may compromise quality of life in survivors. Histologically, Ewing sarcomas are composed of small round cells expressing high levels of CD99. Genetically, they are characterized by balanced chromosomal translocations in which a member of the FET gene family is fused with an ETS transcription factor, with the most common fusion being EWSR1-FLI1 (85% of cases). Ewing sarcoma breakpoint region 1 protein (EWSR1)-Friend leukaemia integration 1 transcription factor (FLI1) is a tumour-specific chimeric transcription factor (EWSR1-FLI1) with neomorphic effects that massively rewires the transcriptome. Additionally, EWSR1-FLI1 reprogrammes the epigenome by inducing de novo enhancers at GGAA microsatellites and by altering the state of gene regulatory elements, creating a unique epigenetic signature. Additional mutations at diagnosis are rare and mainly involve STAG2, TP53 and CDKN2A deletions. Emerging studies on the molecular mechanisms of Ewing sarcoma hold promise for improvements in early detection, disease monitoring, lower treatment-related toxicity, overall survival and quality of life.

Integrity signals

Registry

Crossref · 10.1038/s41572-018-0003-x

Cites

251 of 251 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED ARTICLE: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation
Javaheri, T., Kazemi, Z., Pěnčík, J., Pham, H. T., Kauer, M. O., Noorizadeh, R., Sax, B., Nivarthi, H., Schlederer, M., Maurer, B., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.268 · Cited by 18
Self-citation
Retracted
Bone marrow transplant
Szer, J. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,373
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907
Self-citation
Targeting EZH2 in cancer
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Germline Mutations in Predisposition Genes in Pediatric Cancer
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508054 · Cited by 1,345
MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells
Xu, N., Papagiannakopoulos, T. Y., Pan, G., Thomson, J. A., & Kosik, K. S. (2009) · Cell · doi:10.1016/j.cell.2009.02.038 · Cited by 1,160
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 888
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics
Kadoch, C., & Crabtree, G. R. (2015) · Science Advances · doi:10.1126/sciadv.1500447 · Cited by 877
JHDM2A, a JmjC-Containing H3K9 Demethylase, Facilitates Transcription Activation by Androgen Receptor
Yamane, K., Toumazou, C., Tsukada, Y.-I., Erdjument‐Bromage, H., Tempst, P., Wong, J., & Zhang, Y. (2006) · Cell · doi:10.1016/j.cell.2006.03.027 · Cited by 860

Show all 250 references

Research works printed but not linked: 8

Ewing, J. Diffuse endothelioma of bone. Proc. N. Y. Pathol. Soc. 21, 17 (1921).
Lessnick, S. L., Braun, B. S., Denny, C. T. & May, W. A. Multiple domains mediate transformation by the Ewing’s sarcoma EWS/FLI-1 fusion gene. Oncogene 10, 423–431 (1995).
Ohno, T., Rao, V. N. & Reddy, E. S. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53, 5859–5863 (1993).
Pizzo, P. A. & Poplack, D. G. (eds) Principles and Practice of Pediatric Oncology 7th edn (Lippincott Wililiams & Wilkins, Philadelphia, 2015).
ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl 3), iii113–iii123 (2014).
Machado, I., López-Guerrero, J. A., Scotlandi, K., Picci, P. & Llombart-Bosch, A. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT). Virchows Arch. Int. J. Pathol. 472, 815–824 (2018).
Wang, Y. X. et al. Inhibiting platelet-derived growth factor beta reduces Ewing’s sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 23, 903–909 (2009).
Bhan, A. & Mandal, S. S. LncRNA HOTAIR: a master regulator of chromatin dynamics and cancer. Biochim. Biophys. Acta 1856, 151–164 (2015).

Sorted by citations

A framework for understanding the functions of biomolecular condensates across scales
Lyon, A. S., Peeples, W. B., & Rosen, M. K. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00303-z · Cited by 895
Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 641
Ewing’s Sarcoma
Riggi, N., Suvà, M. L., & Stamenkovic, I. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2028910 · Cited by 374
Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives
Zöllner, S. K., Amatruda, J. F., Bauer, S., Collaud, S., de Álava, E., DuBois, S. G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081685 · Cited by 292
Self-citation
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., Sheffield, N. C., Pierron, G., Lapouble, E., Tötzl, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23445-w · Cited by 200
Self-citation
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 173
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Self-citation
Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution
Aynaud, M.-M., Mirabeau, O., Gruel, N., Grossetête, S., Boeva, V., Durand, S., Surdez, D., Saulnier, O., Zaïdi, S., Gribkova, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.049 · Cited by 160
Self-citation
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008
Dirksen, U., Brennan, B. M. D., Deley, M. L., Cozic, N., van den Berg, H., Bhadri, V. A., Brichard, B., Claude, L., Craft, A. W., Amler, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00915 · Cited by 148
Self-citation
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 140
Fixation can change the appearance of phase separation in living cells
Irgen-Gioro, S., Yoshida, S. R., Walling, V., & Chong, S. (2022) · eLife · doi:10.7554/elife.79903 · Cited by 143
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 132
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma
Zhang, H., Hughes, C. S., Li, W., He, J., Surdez, D., El-Naggar, A. M., Cheng, H., Prudova, A., Delaidelli, A., Negri, G. L., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1690 · Cited by 111
Self-citation
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma
Surdez, D., Zaïdi, S., Grossetête, S., Laud-Duval, K., Ferre, A. S., Mous, L., Vourc’h, T., Tirode, F., Pierron, G., Raynal, V., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.001 · Cited by 106
Self-citation
Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
Morandi, F., Yazdanifar, M., Cocco, C., Bertaina, A., & Airoldi, I. (2020) · Cells · doi:10.3390/cells9081757 · Cited by 103
Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2
Koppenhafer, S. L., Goss, K. L., Terry, W. W., & Gordon, D. J. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0585 · Cited by 96
Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors
Stahl, D. J., Gentles, A. J., Thiele, R., & Gütgemann, I. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1674113 · Cited by 93
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Cillo, A. R., Mukherjee, E., Bailey, N. G., Onkar, S., Daley, J. D., Salgado, C. M., Li, X., Liu, D., Ranganathan, S., Burgess, M. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1471 · Cited by 95
MMP14 in sarcoma: a regulator of tumor microenvironment communication in connective tissues
Gonzalez-Molina, J., Gramolelli, S., Liao, Z., Carlson, J. W., Ojala, P. M., & Lehti, K. (2019) · Cells · doi:10.3390/cells8090991 · Cited by 89
Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation
Orth, M. F., Surdez, D., Faehling, T., Ehlers, A. C., Marchetto, A., Grossetête, S., Volckmann, R., Zwijnenburg, D. A., Gerke, J. S., Zaïdi, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111761 · Cited by 90
Self-citation
EWSR1/FUS-NFATc2 rearranged round cell sarcoma: clinicopathological series of 4 cases and literature review
Díaz-Pérez, J. A., Nielsen, G. P., Antonescu, C. R., Taylor, M. S., Lozano‐Calderón, S. A., & Rosenberg, A. E. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.05.001 · Cited by 87
PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum
Al-Halabi, K., Stichel, D., Sievers, P., Peterziel, H., Sommerkamp, A. C., Sturm, D., Wittmann, A., Sill, M., Jäger, N., Beck, P., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02354-8 · Cited by 89
ETS transcription factors as emerging drug targets in cancer
Hsing, M., Wang, Y. Z., Rennie, P. S., Cox, M., & Cherkasov, A. R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21575 · Cited by 87
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
Bailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79
p53 induces circFRMD4A to suppress cancer development through glycolytic reprogramming and cuproptosis
Liao, Q., Deng, J., Tong, J., Gan, Y., Hong, W., Dong, H., Cao, M., Chen, X., Chen, Y., Xie, B., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.11.013 · Cited by 80
International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines
Abib, S. D. C. V., Chui, C. H., Cox, S. G., Abdelhafeez, A. H., Fernández‐Pineda, I., Elgendy, A., Karpelowsky, J. S., Lobos, P. A., Wijnen, M., Fuchs, J., et al. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1356 · Cited by 78
Dissolution of oncofusion transcription factor condensates for cancer therapy
Wang, Y., Yu, C., Pei, G., Jia, W., Li, T., & Li, P. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01376-5 · Cited by 74
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
Musa, J., Cidre‐Aranaz, F., Aynaud, M.-M., Orth, M. F., Knott, M. M. L., Mirabeau, O., Mazor, G., Varon, M., Hölting, T. L. B., Grossetête, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12071-2 · Cited by 72
Self-citation
Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies
Knott, M. M. L., Hölting, T. L. B., Ohmura, S., Kirchner, T., Cidre‐Aranaz, F., & Grünewald, T. G. P. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09839-9 · Cited by 72
Self-citation
Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells
Solé, A. S., Grossetête, S., Heintzé, M., Babin, L., Zaïdi, S., Revy, P., Renouf, B., Cian, A. D., Giovannangeli, C., Pierre‐Eugène, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3837 · Cited by 72
Self-citation
DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma
Koelsche, C., Kriegsmann, M., Kommoss, F. K. F., Stichel, D., Kriegsmann, K., Vokuhl, C., Grünewald, T. G. P., Romero‐Pérez, L., Kirchner, T., de Álava, E., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02895-2 · Cited by 72
Self-citation
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
Pararajalingam, P., Coyle, K. M., Arthur, S. E., Thomas, N., Alcaide, M., Meissner, B., Boyle, M., Qureshi, Q., Grande, B. M., Rushton, C. K., et al. (2020) · Blood · doi:10.1182/blood.2019002385 · Cited by 73
Bone tumors: a systematic review of prevalence, risk determinants, and survival patterns
Hosseini, H., Heydari, S., Hushmandi, K., Daneshi, S., & Raesi, R. (2025) · BMC Cancer · doi:10.1186/s12885-025-13720-0 · Cited by 70
Genetic Predisposition to Solid Pediatric Cancers
Capasso, M., Montella, A., Tirelli, M., Maiorino, T., Cantalupo, S., & Iolascon, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590033 · Cited by 68
EWSR1-NFATC2 and FUS-NFATC2 Gene Fusion-Associated Mesenchymal Tumors: Clinicopathologic Correlation and Literature Review
Bode‐Lesniewska, B., Fritz, C., Exner, G. U., Wagner, U., & Fuchs, B. (2019) · Sarcoma · doi:10.1155/2019/9386390 · Cited by 65
Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma
Marchetto, A., Ohmura, S., Orth, M. F., Knott, M. M. L., Colombo, M. V., Arrigoni, C., Bardinet, V., Saucier, D., Wehweck, F. S., Li, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16244-2 · Cited by 64
Self-citation
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Dallmayer, M., Li, J., Ohmura, S., Rubío, R. A., Baldauf, M. C., Hölting, T. L. B., Musa, J., Knott, M. M. L., Stein, S., Cidre‐Aranaz, F., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1372-0 · Cited by 65
Self-citation
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges
Hsu, J. Y., Seligson, N. D., Hays, J. L., Miles, W. O., & Chen, J. L. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00211 · Cited by 60
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells
Bierbaumer, L., Katschnig, A. M., Radic-Sarikas, B., Kauer, M. O., Petro, J. A., Högler, S., Gurnhofer, E., Pedot, G., Schäfer, B. W., Schwentner, R., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00294-8 · Cited by 63
Self-citation
NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker
Perret, R. E., Escuriol, J., Velasco, V., Mayeur, L., Soubeyran, I., Delfour, C., Aubert, S., Polivka, M., Karanian, M., Meurgey, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0542-z · Cited by 60
Biodegradable polymers: an update on drug delivery in bone and cartilage diseases
Lima, A. C., Ferreira, H., Reis, R. L., & Neves, N. M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1635117 · Cited by 61
RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stressPreprint
Su, X. A., Ma, D., Parsons, J. V., Replogle, J. M., Amatruda, J. F., Whittaker, C. A., Stegmaier, K., & Amon, A. (2021) · Genes & Development · doi:10.1101/gad.345454.120 · Cited by 57
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
Lopez, C. K., Noguera, E., Stavropoulou, V., Robert, E., Aid, Z., Ballerini, P. F., Bilhou‐Nabera, C., Lapillonne, H., Boudia, F., Thirant, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1463 · Cited by 59
The Involvement of Long Non-Coding RNAs in Bone
Aurilia, C., Donati, S., Palmini, G., Miglietta, F., Iantomasi, T., & Brandi, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083909 · Cited by 56
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma
Koch, R., Gelderblom, H. A. J., Haveman, L., Brichard, B., Jürgens, H., Cyprova, S., van den Berg, H., Hassenpflug, W., Raciborska, A., Ek, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01942 · Cited by 54
Self-citation
Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma
Evdokimova, V. E., Gassmann, H., Radvanyi, L. G., & Burdach, S. E. G. (2022) · Cancers · doi:10.3390/cancers15010272 · Cited by 58
TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma
Casey, D. L., Pitter, K. L., Wexler, L. H., Slotkin, E. K., Gupta, G. P., & Wolden, S. L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01438-2 · Cited by 51
Emerging therapies in Ewing sarcoma
Strauss, S. J., Berlanga, P., & McCabe, M. G. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001048 · Cited by 52
The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review
Apfelbaum, A. A., Wrenn, E. D., & Lawlor, E. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1044707 · Cited by 54
Fuzzy Drug Targets: Disordered Proteins in the Drug-Discovery Realm
Saurabh, S., Nadendla, K., Purohit, S. S., Sivakumar, P. M., & Çetinel, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c07708 · Cited by 51
Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes
Gillani, R., Camp, S. Y., Han, S., Jones, J. K., Chu, H., O’Brien, S., Young, E. L., Hayes, L., Mitchell, G., Fowler, T., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.04.007 · Cited by 54
Exosomes in Bone Sarcomas: Key Players in Metastasis
Chicón‐Bosch, M., & Tirado, Ò. M. (2020) · Cells · doi:10.3390/cells9010241 · Cited by 50
Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas
Menéndez, S. T., Gallego, B., Murillo, D., Rodríguez, A., & Rodrı́guez, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122621 · Cited by 48
Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma
Ohmura, S., Marchetto, A., Orth, M. F., Li, J., Jabar, S., Ranft, A., Vinca, E., Ceranski, A. K., Carreño-Gonzalez, M. J., Romero‐Pérez, L., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01393-9 · Cited by 48
Self-citation
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma
Shulman, D. S., Whittle, S. B., Surdez, D., Bailey, K. M., de Álava, E., Yustein, J. T., Shlien, A., Hayashi, M., Bishop, A. J. R., Crompton, B. D., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00307-2 · Cited by 54
Self-citation
Small round cell sarcomas
Cidre‐Aranaz, F., Watson, S., Amatruda, J. F., Nakamura, T., Delattre, O., de Álava, E., Dirksen, U., & Grünewald, T. G. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00393-3 · Cited by 51
Self-citation
Coupling Lipid Labeling and Click Chemistry Enables Isolation of Extracellular Vesicles for Noninvasive Detection of Oncogenic Gene Alterations
Sun, N., Tran, B. V., Peng, Z., Wang, J., Zhang, C., Yang, P., Zhang, T. X., Widjaja, J., Zhang, R. Y., Xia, W., et al. (2022) · Advanced Science · doi:10.1002/advs.202105853 · Cited by 46
Comparative international incidence of Ewing sarcoma 1988 to 2012
Spector, L. G., Hubbard, A. K., Diessner, B. J., Machiela, M. J., Webber, B. R., & Schiffman, J. D. (2021) · International Journal of Cancer · doi:10.1002/ijc.33674 · Cited by 45
Oncogenic ETS Factors in Prostate Cancer
Nicholas, T. R., Strittmatter, B. G., & Hollenhorst, P. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_18 · Cited by 49
A Nomogram for Predicting Cancer-Specific Survival of Osteosarcoma and Ewing's Sarcoma in Children: A SEER Database Analysis
Wang, J., Zhanghuang, C., Tan, X., Mi, T., Liu, J., Jin, L., Li, M., Zhang, Z., & He, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.837506 · Cited by 44
Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
Shi, J., Yang, J., Ma, X., & Wang, X. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01607-8 · Cited by 44
The ETS transcription factor ETV6 constrains the transcriptional activity of EWS–FLI to promote Ewing sarcoma
Lu, D. Y., Ellegast, J. M., Ross, K. N., Malone, C. F., Lin, S., Mabe, N. W., Dharia, N. V., Meyer, A., Conway, A. S., Su, A. H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01059-8 · Cited by 49
Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma
Lu, C., Mahajan, A., Hong, S.-H., Galli, S., Zhu, S., Tilan, J. U., Abualsaud, N., Adnani, M. T., Chung, S., Elmansy, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29898-x · Cited by 43
Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions
Vibert, J., Saulnier, O., Collin, C., Petit, F., Borgman, K. J. E., Vigneau, J., Gautier, M., Zaïdi, S., Pierron, G., Watson, S., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.019 · Cited by 43
Self-citation
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma
Meyers, P. A., Federman, N. C., Daw, N. C., Anderson, P. M., Davis, L. E., Kim, A., Macy, M. E., Pietrofeso, A., Ratan, R., Riedel, R. F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00020 · Cited by 40
Ewing sarcoma from molecular biology to the clinic
Dupuy, M., Lamoureux, F., Mullard, M., Postec, A., Regnier, L., Baud’huin, M., Georges, S., Royer, B. B.-L., Ory, B., Rédiní, F., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1248753 · Cited by 44
Coupling Nanostructured Microchips with Covalent Chemistry Enables Purification of Sarcoma‐Derived Extracellular Vesicles for Downstream Functional Studies
Dong, J., Zhang, R. Y., Sun, N., Hu, J., Smalley, M. D., Zhou, A., Hua, Y., Rothermich, W., Chen, M., Chen, J., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003237 · Cited by 41
Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells
Visser, L. L., Bleijs, M., Margaritis, T., van de Wetering, M., Holstege, F. C. P., & Clevers, H. C. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0027 · Cited by 42
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 41
Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth
Vasileva, E., Warren, M., Triche, T. J., & Amatruda, J. F. (2022) · eLife · doi:10.7554/elife.69734 · Cited by 40
Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1324 · Cited by 39
Self-citation
Osteoporosis in Childhood Cancer Survivors: Physiopathology, Prevention, Therapy and Future Perspectives
Rossi, F., Tortora, C., Paoletta, M., Marrapodi, M. M., Argenziano, M., Paola, A. D., Pota, E., Pinto, D., Martino, M. D., & Iolascon, G. (2022) · Cancers · doi:10.3390/cancers14184349 · Cited by 40
18 F‐FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta‐analysis
Seth, N., Seth, I., Bulloch, G., Siu, A. H. Y., Guo, A., Chatterjee, R., MacManus, M. P., & Donnan, L. T. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29415 · Cited by 38
Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment
Wrenn, E. D., Apfelbaum, A. A., Rudzinski, E. R., Deng, X., Jiang, W. H., Sud, S., Noord, R. A. V., Newman, E. A., Garcia, N. M., Miyaki, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1111 · Cited by 48
Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy
Romo‐Morales, A., Aładowicz, E., Blagg, J., Gatz, S. A., & SHIPLEY, J. M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27888 · Cited by 38
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
Shulman, D. S., Merriam, P. A., Choy, E., Guenther, L. M., Cavanaugh, K. L., Kao, P., Posner, A., Bhushan, K., Fairchild, G., Barker, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6208 · Cited by 37
Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials
Tang, F., Tie, Y., Wei, Y.-Q., Tu, C., & Wei, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188606 · Cited by 39
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Flores, G., & Grohar, P. J. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100404 · Cited by 39
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
Costa, M. E. M. D., Zaïdi, S., Scoazec, J., Droit, R., Lim, W. C., Marchais, A., Salmon, J., Cherkaoui, S., Morscher, R. J., Laurent, A. P., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05320-0 · Cited by 35
Self-citation
A nomogram to predict prognosis in Ewing sarcoma of bone
Zhou, Q., Wu, Z., & Lin, Z.-Q. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100223 · Cited by 35
Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
Scotlandi, K., Hattinger, C. M., Pellegrini, E., Gambarotti, M., & Serra, M. (2020) · Cells · doi:10.3390/cells9040968 · Cited by 41
Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review
Campbell, K. M., Shulman, D. S., Grier, H. E., & DuBois, S. G. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28807 · Cited by 36
The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis
Tzanakakis, G. N., Giatagana, E.-M., Berdiaki, A., Spyridaki, I., Hida, K., Neagu, M. T., Tsatsakis, A. M., & Nikitovic, D. (2021) · Cancers · doi:10.3390/cancers13102478 · Cited by 38
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
Albarrán, V., Villamayor, M. L., Chamorro, J., Rosero, D. I., Pozas, J., Román, M. S., Calvo, J. C., de Aguado, P. P., Moreno, J. A., Guerrero, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213784 · Cited by 37
ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation
Gao, Y., He, X., Wu, X., Huang, Y., Toneyan, S., Ha, T., Ipsaro, J. J., Koo, P. K., Joshua‐Tor, L., Bailey, K. M., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01060-1 · Cited by 36
Circulating cell-free tumor DNA analysis in pediatric cancers
Andersson, D., Fagman, H., Dalin, M. G., & Ståhlberg, A. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.003 · Cited by 37
In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues
Young, L. E. A., Conroy, L. R., Clarke, H. A., Hawkinson, T. R., Bolton, K. E., Sanders, W. C., Chang, J. E., Webb, M. B., Alilain, W. J., Kooi, C. W. V., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216029 · Cited by 33
18F-FDG PET-CT versus MRI for detection of skeletal metastasis in Ewing sarcoma
Bosma, S. E., Vriens, D., Gelderblom, H. A. J., van de Sande, M. A. J., Dijkstra, P. D. S., & Bloem, J. L. (2019) · Skeletal Radiology · doi:10.1007/s00256-019-03192-2 · Cited by 34
RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis
Sánchez-Molina, S., Figuerola-Bou, E., Blanco, E., Sánchez-Jiménez, M., Táboas, P., Gómez‐González, S., Ballaré, C., García-Domínguez, D. J., Prada, E., Hontecillas‐Prieto, L., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba3058 · Cited by 33
Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function
Gassmann, H., Schneider, K., Evdokimova, V. E., Ruzanov, P., Schober, S. J., Xue, B., von Heyking, K., Thiede, M., Richter, G. H. S., Pfaffl, M. W., et al. (2021) · Cells · doi:10.3390/cells10082081 · Cited by 36
Self-citation
Combinatorial drug screening on 3D Ewing sarcoma spheroids using droplet-based microfluidics
Fevre, R., Mary, G., Vertti‐Quintero, N., Durand, A., Tomasi, R. F.-X., Nery, E. D., & Baroud, C. N. (2023) · iScience · doi:10.1016/j.isci.2023.106651 · Cited by 33
Neuropeptide Y in cancer—biological functions and potential clinical implications
Sigorski, D., Sejda, A., Abualsaud, N., Krawczyk, E., Iżycka‐Świeszewska, E., & Kitlinska, J. B. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10237-z · Cited by 36
Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients
Sannino, G., Marchetto, A., Ranft, A., Jabar, S., Zacherl, C., Rubío, R. A., Stein, S., Wehweck, F. S., Kıran, M. M., Hölting, T. L. B., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.002 · Cited by 34
Self-citation
A comprehensive overview of liquid biopsy applications in pediatric solid tumors
Janssen, F. W., Lak, N. S. M., Janda, C. Y., Kester, L. A., Meister, M. T., Merks, J. H. M., van den Heuvel-Eibrink, M. M., van Noesel, M. M., Zsiros, J., Tytgat, G. A. M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00657-z · Cited by 32
Tissue engineered models of healthy and malignant human bone marrow
Chramiec, A. G., & Vunjak‐Novakovic, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.003 · Cited by 33
Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells
Kerschner-Morales, S. L., Kühne, M., Becker, S., Beck, J. F., & Sonnemann, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03346-z · Cited by 32
Gastroblastoma with a novel EWSR1‐CTBP1 fusion presenting in adolescence
Koo, S. C., LaHaye, S., Kovari, B. P., Schieffer, K. M., Ranalli, M. A., Aldrink, J. H., Michalsky, M. P., Colace, S. I., Miller, K. E., Bedrosian, T. A., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22973 · Cited by 32
KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
Chen, B., Chen, H., Lü, S., Zhu, X., Que, Y., Zhang, Y., Huang, J., Zhang, L., Zhang, Y., Sun, F., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04800-1 · Cited by 31
Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1 ‐opposing gene signature and associate with disease progression in Ewing sarcoma
Rodríguez‐Núñez, P., Romero‐Pérez, L., Amaral, A. T., Puerto‐Camacho, P., Jordán, C., Marcilla, D., Grünewald, T. G. P., Alonso, J., de Álava, E., & Díaz‐Martín, J. (2019) · The Journal of Pathology · doi:10.1002/path.5379 · Cited by 33
Self-citation

Authors: Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U.
Affiliations: German Cancer Research Center (DE)
Inserm (FR)
St. Anna Children's Cancer Research Institute (AT)
University of British Columbia (CA)
Corresponding author: Grünewald, Thomas G. P.
ORCID: Grünewald, Thomas G. P.
Surdez, Didier
Tomazou, Eleni M.
Kovar, Heinrich
Sorensen, Poul H.
Delattre, Olivier
Dirksen, Uta
Venue: Nature Reviews Disease Primers
Publisher: Springer Science and Business Media LLC
Published: 2018-07-05
Volume: 4
Issue: 1
Pages: 5-5
ISSN: 2056-676X (ISSN-L)
DOI: 10.1038/s41572-018-0003-x
OpenAlex: W4211227438
Cited by: 873
References: 250
Citations by year: 2026: 114 · 2025: 155 · 2024: 104 · 2023: 103 · 2022: 158 · 2021: 115 · 2020: 66 · 2019: 49 · 2018: 8
FWCI: 10.61
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Disease Primers (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: Ewing sarcoma, EWSR1-FLI1 fusion, CD99, epigenetic reprogramming, STAG2 mutation, TP53 mutation, CDKN2A deletion, treatment toxicity, cancer survivorship, soft tissue sarcoma
MeSH terms: 12E7 Antigen, Humans, Neoplasm Metastasis, Quality of Life, Radiography, Risk Factors, Sarcoma, Ewing, RNA-Binding Protein EWS, Proto-Oncogene Protein c-fli-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ewing sarcoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks